Aerie Pharmaceuticals Inc


Aerie Pharmaceuticals Inc (AERI) Moves a Step Closer to Glaucoma Drug

After market close yesterday, Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced positive 3-month top-line efficacy results from its pivotal phase III Mercury 2 trial for glaucoma eye …

After-Hours Buzz: Interpace Diagnostics Group Inc (IDXG), Aerie Pharmaceuticals Inc (AERI)

Interpace Diagnostics Group Inc (NASDAQ:IDXG) shares rose nearly 8% in after-hours trading Wednesday, after the company announced that it is launching a new biomarker …

Company Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Enters Into Lease Agreement With IDA Of Ireland For First Manufacturing Plant

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced that it has entered into a lease agreement with the Industrial Development Agency (IDA) of Ireland for a …

Needham Bullish on Aerie Pharmaceuticals Inc (AERI) Despite NDA Filing Delay for Rhopressa

Needham’s Serge Belanger has reiterated his Buy rating on Aerie Pharma (NASDAQ: AERI) despite a stalled manufacturing pre-inspection that has caused the firm to delay …

Canaccord Assumes a Buy on Aerie Pharmaceuticals Inc (AERI)

Dewey Steadman at research firm Canaccord has come out with a bullish call on shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI). The analyst assumed …

Stock Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Provides Update on Timing of NDA Filing for Rhopressa

Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported that it has been notified by its third party manufacturing vendor that the manufacturing line related to Rhopressa in …

Stock Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Announces Appointment of Judith J. Robertson as Chief Commercial Officer

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the appointment of Judith J. Robertson as Chief Commercial Officer, reporting to Thomas Mitro, Aerie President and Chief …

Stock Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the completion of patient enrollment in the Company’s second Phase 3 registration trial (“Mercury 2”) of Roclatan (netarsudil/latanoprost …

Stock Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of RhopressaTM 0.02%

Aerie Pharmaceuticals Inc (NASDAQ:AERI) reported the successful 90-day topline efficacy results of its Rocket 4 Phase 3 clinical trial of product candidate RhopressaTM, a …

Company Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Raises $125 Million in Public Offerings

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts